Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics

Article Gastroenterology & Hepatology

Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease

Lidia Serrano Diaz et al.

Summary: Proactive therapeutic drug monitoring using Bayesian approach improves the efficacy of treatment and reduces long-term complications in patients with inflammatory bowel disease.

GASTROENTEROLOGIA Y HEPATOLOGIA (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Model-informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease

Ruben J. Colman et al.

Summary: This study emphasizes the integration of a precision dosing dashboard within the electronic health record as a multidisciplinary effort to individualize biologic exposure starting and during induction, addressing the issue of inconsistent biologic therapeutic response related to pharmacokinetic variability between patients.

INFLAMMATORY BOWEL DISEASES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases

Wannee Kantasiripitak et al.

Summary: The study aimed to develop a multi-model model-based software tool for guiding personalized infliximab induction treatment in pediatric inflammatory bowel disease patients. The study found that using the tool for individualized dosing improved the chances for children to achieve deep remission at 6 months.

JOURNAL OF CROHNS & COLITIS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance

Ruben J. Colman et al.

Summary: This study established a pediatric vedolizumab pharmacokinetic model to optimize dosing. By analyzing fecal microbiota, it was found that an early abundance of butyrate-producing bacteria was associated with patients' response to vedolizumab.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis

Ana Victoria Ponce-Bobadilla et al.

Summary: This study assessed the performance of immunogenicity assays in predicting low adalimumab concentration in patients with Crohn's disease and ulcerative colitis, and developed a robust population PK model for CD and UC patients impacted by anti-drug antibodies.

CLINICAL PHARMACOKINETICS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis

Kaitlin G. Whaley et al.

Summary: This study aimed to model the pharmacokinetics of infliximab (IFX) in pediatric acute severe ulcerative colitis (ASUC) and assess the association between IFX exposure and clinical response. The results showed that IFX exposure was not predictive of clinical outcomes in pediatric ASUC, and a higher initial dose may optimize early outcomes.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Population Pharmacokinetic and Exposure-Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease

Ahmed Abbas Suleiman et al.

Summary: Population pharmacokinetics of risankizumab were characterized using data from phase II and III studies in patients with Crohn's disease. Exposure-response analyses showed that the 600 mg intravenous (i.v.) induction dose achieved a near maximal response for all efficacy end points. The maintenance treatment of 360 mg subcutaneous every-8-weeks (Q8W) regimen showed higher responses for most of the evaluated efficacy end points.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Early Infliximab Clearance Predicts Remission in Children with Crohn's Disease

Aaron Chung et al.

Summary: Early infliximab clearance is strongly associated with remission in children with Crohn's disease and may serve as a predictive marker for treatment outcomes.

DIGESTIVE DISEASES AND SCIENCES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically

Emily K. Wright et al.

Summary: This study found that adalimumab drug clearance is a critical factor in determining the therapeutic outcome of Crohn's disease patients. Patients with lower drug clearance showed better endoscopic remission, while drug concentration did not significantly differ between patients in remission and those with recurrence. Sustained clinical remission based on C-reactive protein and lower faecal calprotectin levels were generally associated with lower clearance and higher drug concentration.

JOURNAL OF CROHNS & COLITIS (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies

Laiyi Chua et al.

Summary: This study characterized the pharmacokinetics of mirikizumab, a monoclonal antibody, in patients with ulcerative colitis. The pharmacokinetic profile of mirikizumab was in line with the typical characteristics of a monoclonal antibody, with clearance increasing with body weight and decreasing with albumin level, and bioavailability decreasing with body mass index.

CLINICAL PHARMACOKINETICS (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Physiologically-Based Pharmacokinetic Modeling of Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants

Jiarui Chen et al.

Summary: This study developed a physiologically-based pharmacokinetic model to predict the pharmacokinetics of anti-tumor necrosis factor agents in pregnant women, fetuses, and infants. The model successfully provided optimal timing for drug dosing during pregnancy and recommended vaccination schedules for infants.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease

Ruben J. Colman et al.

Summary: This study evaluated the impact of ATI on infliximab clearance and loss of response, finding that even low levels of ATI can affect drug clearance. The data suggest that dose optimization for low-level ATI can improve infliximab clearance and prevent loss of response.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Oncology

A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease

Pavine L. C. Lefevre et al.

Summary: Certolizumab pegol (CZP) is effective for Crohn's disease, with higher plasma concentrations linked to better outcomes and increased drug clearance driving suboptimal concentrations. A prediction model incorporating CZP clearance and patient variables can estimate the probability of remission prior to therapy initiation. Patient-level probabilities for composite remission outcomes can be predicted using online clinical decision support tools by entering common patient- and disease-related factors.

BIODRUGS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

REAL-WORLD VEDOLIZUMAB PHARMACOKINETIC STUDY IN CHILDREN IDENTIFIES TWO NOVEL BIOMARKERS OF DRUG CLEARANCE

Ruben Colman et al.

GASTROENTEROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity

Marla C. Dubinsky et al.

Summary: This study presents the first proactive optimization of infliximab dosing during induction, guided by a pharmacokinetics dashboard, in a real-world inflammatory bowel disease setting. It found that the timing of the first maintenance infusion significantly impacted clinical outcomes, demonstrating that optimizing dosing early can improve the durability and immunogenicity of infliximab.

INFLAMMATORY BOWEL DISEASES (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease

Zhigang Wang et al.

Summary: Based on population pharmacokinetic-pharmacodynamic analysis, different ustekinumab dosage regimens have varying impacts on endoscopic outcomes in patients with Crohn's disease, guiding clinical trial design and individualized dose optimization.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study

Niels Vande Casteele et al.

Summary: The study aimed to evaluate the relationship between intravenous vedolizumab exposure and treatment outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD). The results showed a positive relationship between vedolizumab concentration and clinical remission, with early induction concentration being an important predictor of short- and long-term outcomes.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study

Jurij Hanzel et al.

Summary: Higher serum concentrations of vedolizumab have been associated with improved outcomes in inflammatory bowel disease. A pharmacokinetic-pharmacodynamic model linking vedolizumab exposure to endoscopic remission in Crohn disease was developed in this study, suggesting that linear clearance was higher and vedolizumab exposure was lower in patients with certain conditions. Model-based simulations implied that optimized dosing of vedolizumab could maximize endoscopic remission rates in CD patients.

INFLAMMATORY BOWEL DISEASES (2022)

添加到收藏夹

Article Medicine, General & Internal

Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases

Christian Primas et al.

Summary: This study evaluated the performance of a Model Informed Precision Dosing (MIPD) Tool in forecasting Infliximab (IFX) levels in patients with Inflammatory Bowel Diseases (IBD). The results showed that serum TNF-alpha and CRP were associated with IFX levels and played an important role in predicting treatment outcomes.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases

Wannee Kantasiripitak et al.

Summary: In patients with inflammatory bowel diseases, using a model averaging algorithm based on maximum a posteriori prediction shows better predictive performance for Infliximab dosage de-escalation compared to a model selection algorithm or a single-model approach. Only a single trough concentration is necessary for accurate and precise prediction, and the predictive performance is robust to the lack of covariate data.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease

Omoniyi J. Adedokun et al.

Summary: This study evaluated the pharmacokinetics and dose-response relationship of ustekinumab in patients with Crohn's disease. The results showed that the metabolism of ustekinumab in patients is influenced by multiple factors, but these effects do not have clinical significance on ustekinumab exposure. In addition, a positive correlation was established between ustekinumab concentration and efficacy outcomes.

CLINICAL THERAPEUTICS (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease

Erwin Dreesen et al.

Summary: Evidence for the benefits of pharmacokinetic (PK) and pharmacodynamic (PD) monitoring of infliximab in patients with Crohn's disease (CD) remains scarce. By developing a population (pop)PK/PD model, the study aimed to characterize the infliximab dose-exposure-biomarker-response relationship. Results showed that infliximab clearance and baseline fCal were influenced by various factors, with large interpatient PK and PD variability resulting in a flat dose-response curve. Model-informed dose optimization may improve the effectiveness of infliximab therapy.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Bayes-based dosing of infliximab in inflammatory bowel diseases: Short-term efficacy

Eugenia Santacana Juncosa et al.

Summary: Therapeutic drug monitoring of infliximab combined with Bayesian forecasting methodology can effectively improve clinical responses in patients with inflammatory bowel disease. Optimized dosing of infliximab through this approach helps increase remission rates and overall treatment efficacy for these patients.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis

Jurij Hanzel et al.

Summary: The study characterized the pharmacokinetics of subcutaneous CT-P13 through population PK modeling, identifying body weight, presence of anti-drug antibodies, and serum albumin concentration as clinically relevant covariates affecting drug clearance. Simulated drug exposure demonstrated differences between routes of administration in patients of varying body weights.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Letter Pharmacology & Pharmacy

Letter to Dreesen et al. on their article Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Disease-A comprehensive review of infliximab population pharmacokinetic modelling publications

Olivier Le Tilly et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management

Ana-Marija Grisic et al.

Summary: This study established a strong relationship between IFX exposure and CRP synthesis inhibition, which could be utilized for treatment optimization in IBD patients. Results showed that presence of ADA was the most influential factor on IFX exposure, and shortening the dosing interval and co-therapy with immunomodulators were found to be the most beneficial strategies to maintain CRP remission.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease

Ye Xiong et al.

Summary: The study identified blood biomarkers for rapid clearance and exposure targets of infliximab in pediatric Crohn's disease. Higher AUC during induction was associated with better treatment outcomes and lower surgery rates for patients.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies

Konstantinos Papamichael et al.

Summary: Therapeutic drug monitoring (TDM) is beneficial for optimizing monoclonal antibodies (mAbs) in the treatment of immune-mediated inflammatory disorders, but faces challenges such as long turnaround times and high PK variability. Overcoming these barriers may involve point-of-care testing, model-informed precision dosing, and pharmacogenetics/pharmacogenomics. Recent advances include POC assays and PK dashboards, with future perspectives focusing on personalized implementation of TDM incorporating pharmacogenetics to benefit specific patient subgroups. Challenges remain in implementing these innovative approaches, requiring more data from prospective studies and randomized controlled trials.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial

Anne S. Strik et al.

Summary: In IBD patients, using a Bayesian dashboard for IFX dosing can reduce the incidence of LOR and lower fecal calprotectin levels. Additionally, this method can increase the proportion of patients in sustained clinical remission.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Stefan Schreiber et al.

Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.

GASTROENTEROLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases

Wannee Kantasiripitak et al.

Summary: During clearance monitoring, mAb clearance is calculated and monitored over time, which can be associated with higher target load, protein-losing enteropathy, and immunogenicity in patients with IBD. Although not confirmed, clearance monitoring could help identify asymptomatic disease flares or undetectable anti-drug antibodies, and predict treatment outcomes. The potential of dosage regimen adjustments in modifying clearance time course and treatment outcomes needs further investigation.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model

Jurij Aguiar Zdovc et al.

Summary: The study developed a population PK-PD model for ustekinumab in Crohn's disease and found associations between certain patient characteristics and drug exposure. Model-based simulations showed that transitioning to 4-weekly subcutaneous maintenance dosing could improve remission rates for patients who did not achieve remission with standard dosing.

PHARMACEUTICS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease

Hiroyuki Okamoto et al.

Summary: This study analyzed the pharmacokinetics of vedolizumab in Asian and non-Asian UC and CD patients, finding similar pharmacokinetic parameters between the two groups. The results support the use of the same dosage of vedolizumab in these patients.

INTESTINAL RESEARCH (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease

Laura E. Bauman et al.

INFLAMMATORY BOWEL DISEASES (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics

Katsuyoshi Matsuoka et al.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis

Yan Xu et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Baseline Clearance of Infliximab is Associated with Requirement for Colectomy in Patients with Acute Severe Ulcerative Colitis

Robert Battat et al.

Clinical Gastroenterology and Hepatology (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues

Zhigang Wang et al.

CURRENT OPINION IN PHARMACOLOGY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De-Escalation in Adults With Inflammatory Bowel Diseases

Antoine Petitcollin et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study

Niels Vande Casteele et al.

JOURNAL OF CROHNS & COLITIS (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

Mark T. Osterman et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis

Niels Vande Casteele et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis

Yan Xu et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot Study

Antoine Petitcollin et al.

INFLAMMATORY BOWEL DISEASES (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System

Alexander Eser et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis

David Kevans et al.

JOURNAL OF CROHNS & COLITIS (2018)

添加到收藏夹

Article Medical Laboratory Technology

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease

Sophie E. Berends et al.

THERAPEUTIC DRUG MONITORING (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration

Helena Edlund et al.

AAPS JOURNAL (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients

Marla C. Dubinsky et al.

AAPS JOURNAL (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease

Johannan F. Brandse et al.

INFLAMMATORY BOWEL DISEASES (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease

Niels Vande Casteele et al.

CLINICAL PHARMACOKINETICS (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Efficacy and Safety Profile of Anti tumor Necrosis Factor-α Versus Anti-integrin Agents for, the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons

Michael Miligkos et al.

CLINICAL THERAPEUTICS (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

M. Rosario et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice

D. J. Buurman et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)

添加到收藏夹

Letter Pharmacology & Pharmacy

Pharmacokinetics of adalimumab in Crohn's disease

David Ternant et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Pharmacokinetics and Exposure-Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohn's Disease: Results from a Randomized, Multicenter, Phase-3 Study

Shringi Sharma et al.

INFLAMMATORY BOWEL DISEASES (2015)

添加到收藏夹

Review Gastroenterology & Hepatology

Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse

Konstantinos Papamichael et al.

INFLAMMATORY BOWEL DISEASES (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative Colitis: Results from a Randomized, Multicenter, Open-label, Phase 3 Study

Omoniyi J. Adedokun et al.

INFLAMMATORY BOWEL DISEASES (2013)

添加到收藏夹

Article Pharmacology & Pharmacy

Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials

Adedigbo A. Fasanmade et al.

CLINICAL THERAPEUTICS (2011)

添加到收藏夹

Article Pharmacology & Pharmacy

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

A.A. Fasanmade et al.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)

添加到收藏夹

Article Pharmacology & Pharmacy

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

Adedigbo A. Fasanmade et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)

添加到收藏夹

Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics

相关参考文献

导出引文

分享论文